Lyell reports patient death, early responses in solid tumor CAR-T trial
In an early-stage clinical trial with a handful of patients, Lyell Immunopharma’s experimental CAR-T therapy for solid tumor cancers showed hints of efficacy but also …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
